Value-Based Care for Healthy Children With First Episode of Febrile Neutropenia.


Journal

Hospital pediatrics
ISSN: 2154-1671
Titre abrégé: Hosp Pediatr
Pays: United States
ID NLM: 101585349

Informations de publication

Date de publication:
01 Jun 2023
Historique:
medline: 28 11 2023
pubmed: 17 5 2023
entrez: 17 5 2023
Statut: ppublish

Résumé

There is a lack of guidance on the management of febrile neutropenia in otherwise healthy children, including the need for hospitalization and antibiotic administration, leading to significant practice variation in management. The aim of this initiative was to decrease the number of unnecessary hospitalizations and empirical antibiotics prescribed by 50% over a 24-month period for well-appearing, previously healthy patients older than 6 months presenting to the emergency department with a first episode of febrile neutropenia. A multidisciplinary team of stakeholders was assembled to develop a multipronged intervention strategy using the Model for Improvement. A guideline for the management of healthy children with febrile neutropenia was created, coupled with education, targeted audit and feedback, and reminders. Statistical control process methods were used to analyze the primary outcome of the percentage of low-risk patients receiving empirical antibiotics and/or hospitalization. Balancing measures included missed serious bacterial infection, emergency department (ED) return visit, and a new hematologic diagnosis. Over the 44-month study period, the mean percentage of low-risk patients hospitalized and/or who received antibiotics decreased from 73.3% to 12.9%. Importantly, there were no missed serious bacterial infections, no new hematologic diagnoses after ED discharge, and only 2 ED return visits within 72 hours without adverse outcomes. A guideline for the standardized management of febrile neutropenia in low-risk patients increases value-based care through reduced hospitalizations and antibiotics. Education, targeted audit and feedback, and reminders supported sustainability of these improvements.

Identifiants

pubmed: 37194483
pii: 191274
doi: 10.1542/hpeds.2022-007075
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

536-544

Informations de copyright

Copyright © 2023 by the American Academy of Pediatrics.

Auteurs

Charlotte Grandjean-Blanchet (C)

Divisions of Pediatric Emergency Medicine.

Cathie-Kim Le (CK)

Divisions of Pediatric Emergency Medicine.

Stephanie Villeneuve (S)

Hematology/Oncology.

Michaela Cada (M)

Hematology/Oncology.

Carolyn E Beck (CE)

Pediatric Medicine.

Michelle Science (M)

Infectious Diseases, The Hospital for Sick Children, Montreal, Canada.

Daniel Rosenfield (D)

Divisions of Pediatric Emergency Medicine.

Olivia Ostrow (O)

Divisions of Pediatric Emergency Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH